1226145-00-1

Basic information

• Product Name: ethyl 4-(3,5-dichlorophenoxy)-3-oxobutanoate
• Synonyms: ethyl 4-(3,5-dichlorophenoxy)-3-oxobutanoate
• CAS NO: 1226145-00-1
• Molecular Weight: 291.131
• Mol File: 1226145-00-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: ethyl 4-(3,5-dichlorophenoxy)-3-oxobutanoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-(3,5-dichlorophenoxy)-3-oxobutanoate(1226145-00-1)
• EPA Substance Registry System: ethyl 4-(3,5-dichlorophenoxy)-3-oxobutanoate(1226145-00-1)

Safety Data

• Hazardous Substances Data: 1226145-00-1(Hazardous Substances Data)

Upstream product

• 55502-54-0 3,5-dichlorophenoxyacetyl chloride 
• 587-64-4 2-(3,5-dichlorophenoxy)acetic acid 
• 591-35-5 3,5-dichlorophenol 
• 638-07-3 ethyl (2-chloroaceto)acetate 
• 119024-29-2 ethyl 2-(3,5-dichlorophenoxy)acetate 
• 1227692-21-8 2-(3,5-dichlorophenoxy)-N-methoxy-N-methylacetamide 
• 141-78-6 ethyl acetate 

Downstream Products

• 1227692-67-2 5-((3,5-dichlorophenoxy)methyl)-1H-pyrazol-3(2H)-one 
• 1412895-93-2 C₁₂H₁₂Cl₂N₂O₃ 
• 1412895-95-4 C₁₃H₁₄Cl₂N₂O₃ 
• 1412895-97-6 C₁₆H₁₂Cl₂N₂O₂ 
• 1412895-98-7 C₁₆H₁₁Cl₃N₂O₂ 
• 1412895-99-8 C₁₇H₉Cl₄F₃N₂O₂ 
• 1412896-00-4 C₁₆H₁₀Cl₂N₄O₆ 
• 1412896-01-5 C₁₉H₁₃Cl₂N₃O₂S 
• 1412896-02-6 C₁₇H₁₄Cl₂N₂O₂ 
• 1412896-03-7 C₁₇H₁₄Cl₂N₂O₃ 
• 1412896-04-8 C₁₈H₁₆Cl₂N₂O₃ 
• 1412896-05-9 C₁₁H₈Cl₂N₂O₃ 
• 1412896-06-0 C₁₂H₁₀Cl₂N₂O₃ 
• 1412896-07-1 C₁₃H₉Cl₂N₃O₃ 

Relevant articles and documents

ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: Potential application for the treatment of amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis (ALS) is an orphan neurodegenerative disease currently without a cure. The arylsulfanyl pyrazolone (ASP) scaffold was one of the active scaffolds identified in a cell-based high throughput screening assay targeting mutant Cu/

TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS

The present invention relates to the identification of compounds and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the provided compounds.